Menu
← Oncology Approval Tracker
FDA DECISION ·
Padcev + Keytruda
enfortumab vedotin-ejfv + pembrolizumab · Astellas Pharma / Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For locally advanced or metastatic urothelial carcinoma in patients unable to receive cisplatin-containing chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The initial combination approval was limited to cisplatin-ineligible patients and preceded the broader December decision.
What research teams should watch
Document why cisplatin was unsuitable and cite the eligibility rules in effect for the historical action.
PRIMARY RECORDS